Your browser doesn't support javascript.
Prolonged inflammation in patients hospitalized for coronavirus disease 2019 (COVID-19) resolves 2 years after infection.
Fong, Siew-Wai; Goh, Yun Shan; Torres-Ruesta, Anthony; Chang, Zi Wei; Chan, Yi-Hao; Neo, Vanessa Kexin; Lee, Bernett; Duan, Kaibo; Amrun, Siti Naqiah; Yeo, Nicholas Kim-Wah; Chen, Hsiuyi V; Tay, Matthew Zirui; Carissimo, Guillaume; Tan, Seow Yen; Leo, Yee-Sin; Lye, David C; Renia, Laurent; Young, Barnaby Edward; Ng, Lisa F P.
  • Fong SW; A*STAR Infectious Diseases Labs (A*STAR ID Labs), Agency for Science, Technology and Research (A*STAR), Singapore, Singapore.
  • Goh YS; A*STAR Infectious Diseases Labs (A*STAR ID Labs), Agency for Science, Technology and Research (A*STAR), Singapore, Singapore.
  • Torres-Ruesta A; A*STAR Infectious Diseases Labs (A*STAR ID Labs), Agency for Science, Technology and Research (A*STAR), Singapore, Singapore.
  • Chang ZW; A*STAR Infectious Diseases Labs (A*STAR ID Labs), Agency for Science, Technology and Research (A*STAR), Singapore, Singapore.
  • Chan YH; A*STAR Infectious Diseases Labs (A*STAR ID Labs), Agency for Science, Technology and Research (A*STAR), Singapore, Singapore.
  • Neo VK; A*STAR Infectious Diseases Labs (A*STAR ID Labs), Agency for Science, Technology and Research (A*STAR), Singapore, Singapore.
  • Lee B; Singapore Immunology Network (SIgN), Agency for Science, Technology and Research (A*STAR), Singapore, Singapore.
  • Duan K; Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore.
  • Amrun SN; Singapore Immunology Network (SIgN), Agency for Science, Technology and Research (A*STAR), Singapore, Singapore.
  • Yeo NK; A*STAR Infectious Diseases Labs (A*STAR ID Labs), Agency for Science, Technology and Research (A*STAR), Singapore, Singapore.
  • Chen HV; A*STAR Infectious Diseases Labs (A*STAR ID Labs), Agency for Science, Technology and Research (A*STAR), Singapore, Singapore.
  • Tay MZ; A*STAR Infectious Diseases Labs (A*STAR ID Labs), Agency for Science, Technology and Research (A*STAR), Singapore, Singapore.
  • Carissimo G; A*STAR Infectious Diseases Labs (A*STAR ID Labs), Agency for Science, Technology and Research (A*STAR), Singapore, Singapore.
  • Tan SY; A*STAR Infectious Diseases Labs (A*STAR ID Labs), Agency for Science, Technology and Research (A*STAR), Singapore, Singapore.
  • Leo YS; National Centre for Infectious Diseases, Singapore, Singapore.
  • Lye DC; Department of Infectious Diseases, Changi General Hospital, Singapore, Singapore.
  • Renia L; Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore.
  • Young BE; National Centre for Infectious Diseases, Singapore, Singapore.
  • Ng LFP; Department of Infectious Diseases, Tan Tock Seng Hospital, Singapore, Singapore.
J Med Virol ; 95(5): e28774, 2023 05.
Article in English | MEDLINE | ID: covidwho-2323105
ABSTRACT
Long-term complications from coronavirus disease 2019 (COVID-19) are concerning, as survivors can develop subclinical multiorgan dysfunction. It is unknown if such complications are due to prolonged inflammation, and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination may reduce sequela. We conducted a prospective longitudinal study on hospitalized patients over 24 months. Clinical symptoms were collected by self-reporting during follow-up, along with blood samples for quantification of inflammatory markers and immune cell frequencies. All patients were given one dose of mRNA vaccine at 12-16 months. Their immune profiles at 12 and 24 months were compared. Approximately 37% and 39% of our patients reported post-COVID-19 symptoms at 12 and 24 months, respectively. The proportion of symptomatic patients with more than one symptom decreased from 69% at 12 months to 56% at 24 months. Longitudinal cytokine profiling revealed a cluster of individuals with persistently high inflammatory cytokine levels 12 months after infection. Patients with prolonged inflammation showed elevated terminally differentiated memory T cells in their blood; 54% had symptoms at 12 months. The majority of inflammatory markers and dysregulated immune cells in vaccinated patients recovered to a healthy baseline at 24 months, even though symptoms persisted. Post-COVID-19 symptoms can linger for 2 years after the initial infection and are associated with prolonged inflammation. Prolonged inflammation in hospitalized patients resolves after 2 years. We define a set of analytes associated with persistent inflammation and presence of symptoms, which could be useful biomarkers for identifying and monitoring high-risk survivors.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Type of study: Cohort study / Observational study / Prognostic study Topics: Long Covid / Vaccines Limits: Humans Language: English Journal: J Med Virol Year: 2023 Document Type: Article Affiliation country: Jmv.28774

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Type of study: Cohort study / Observational study / Prognostic study Topics: Long Covid / Vaccines Limits: Humans Language: English Journal: J Med Virol Year: 2023 Document Type: Article Affiliation country: Jmv.28774